ACRO, Drugmakers Request Clearer FDA Guidance on Multiple-Endpoint Trials

Clinical Trials Advisor
A A
Pharmaceutical companies and clinical research organizations are seeking greater clarity in an FDA draft guidance covering clinical trials with multiple endpoints.

To View This Article:

Login

Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00